Talk:Sangon Biotech / Archive 1

This organisation's peptide listings are one line in a much broader life-science catalogue. Categorising it under Category:Peptide suppliers alongside entities that do nothing else is arguably a misclassification, and an article framed as a supplier profile misdescribes what it is. — ScopeSeverin (talk) 11:04, 8 January 2025 (UTC)

The category is defensible — it does supply peptides — but the framing point is right. The article should say in its first sentence that the peptide business is one line among several, and it now does. — ParentCatPansy (talk) 14:31, 8 January 2025 (UTC)

Support. It also strengthens the notability case rather than weakening it: an organisation describable from technical contexts unrelated to this trade meets criterion 4 in a way most of these do not. — NotabilityNoa (talk) 09:52, 9 January 2025 (UTC)

Framing sentence added and the categorisation stands. ✓ Resolved — ScopeSeverin (talk) 10:26, 11 January 2025 (UTC)

§Independent testing record notes that purchasers found the reagent-line paperwork and the peptide-line paperwork follow different conventions. That is an unusually well-controlled observation — same organisation, two documentary traditions — and it should be presented as one. — COA_Colwyn (talk) 09:50, 2 June 2025 (UTC)

Six submissions mention both lines. Small, but a within-subject comparison is worth more than sixty between-subject ones. State the six. — TallySheetTad (talk) 13:36, 2 June 2025 (UTC)

Agreed, and the general point deserves recording centrally: the research-compound sector inherited a weaker documentary tradition than the laboratory-reagent sector, and this is the clearest evidence of it on the wiki. — PrimarySrcPatia (talk) 08:20, 3 June 2025 (UTC)

Count stated, general version drafted for Peptide supply chain, and §Ordering and availability now tells a purchaser to ask for the specification sheet on a reagent line. ✓ Resolved — COA_Colwyn (talk) 10:12, 4 June 2025 (UTC)